Deregulation boosts pharma profits by 210% YoY
Given that Covid-19 has pushed renewed focus on health, the demand for active pharmaceutical ingredients (APIs) has never been stronger. PHOTO: FILE
Listen to article
Owing to deregulated prices, Pakistan's pharmaceutical sector witnessed a remarkable surge in profitability, posting a 210% year-on-year (YoY) increase to Rs13.5 billion in the calendar year 2024, according to data compiled by Arif Habib Limited (AHL).
The sector's net revenue increased by 21.1% YoY, reaching Rs196.8 billion, with leading contributions from AGP (+33.8% YoY), Glaxo (+23.2% YoY), and Abbott (+22.9% YoY), according to data gathered by AHL.
"This 210% (or 3.1 times) YoY growth was driven by higher sales volumes and price adjustments following deregulation of drug prices," AHL analyst Menka Kirpalani told The Express Tribune.
Gross profits also saw a significant increase of 64.9% YoY, reaching Rs68.6 billion, supported by better pricing strategies, currency stability, and lower active pharmaceutical ingredient (API) costs. Companies such as Glaxo (+339.2% YoY), Abbott (+67% YoY), and AGP (+44.4% YoY) played a key role in this expansion. The overall gross margin for the sector improved to 34.9%, with Hinoon (51.4%) and AGP (47.8%) leading the way. Net margins also increased to 6.9%, reflecting improved operational efficiency.
The demand-side impact was negligible. Demand for pharmaceuticals and medicines naturally increases as the population grows, said Kirpalani. However, the main issue for the pharmaceutical sector was that their prices were regulated. Essential medicines were subject to a price cap linked to 70% of the Consumer Price Index (CPI) and non-essential medicines to 100% of CPI, meaning companies could only increase prices up to that limit.
In February 2024, the government deregulated prices for the non-essential segment, allowing companies to adjust prices based on their own cost structures and profitability needs. As a result, gross margins improved, and volumes also increased.
Previously, some products had stalled sales due to low marginsfor instance, Panadol was temporarily unavailable because companies were unable to maintain profitability under regulated pricing. With deregulation, both margins and sales have now increased, benefiting the industry.
Despite the positive performance, finance costs grew by 4.7% YoY to Rs4.7 billion, mainly due to higher interest rates. Additionally, other income dropped by 44.4% YoY, impacting companies like Glaxo (-50.8% YoY) and Abbott (-51.6% YoY).
Among individual companies, Glaxo reported a profit of Rs6.5 billion (+12.2 times YoY) with an EPS of Rs20.52, while Abbott recorded Rs5.2 billion (+20 times YoY) with an EPS of Rs53.46. Hinoon posted Rs3.2 billion in profit (+35.4% YoY) with an EPS of Rs61.41, and AGP reported Rs2.08 billion (+75.1% YoY) with an EPS of Rs7.44. However, Searl suffered a loss of Rs3.6 billion, facing operational challenges.
Several companies, including Glaxo, Abbott, and Hinoon, announced dividends of Rs10, Rs10, and Rs40 per share, respectively, rewarding shareholders for the strong financial results.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Express Tribune
17 hours ago
- Express Tribune
PSX makes history on macro boost
Listen to article The Pakistan Stock Exchange (PSX) sustained its bullish streak in the outgoing week, with the benchmark KSE-100 index surging to an all-time high of 121,798 points on June 4, before settling at 121,641, marking a weekly gain of 1,950 points (+1.63%). The rally was fueled by renewed investor confidence following successful budget talks with the International Monetary Fund (IMF), the Asian Development Bank's (ADB) approval of a $800 million financing package and the government's finalisation of a Rs1.275 trillion circular debt resolution deal with banks – a significant development for the energy sector. Macroeconomic indicators further supported sentiment as petroleum sales jumped 10% year-on-year (YoY) in May 2025, the Consumer Price Index (CPI)-based inflation eased to 3.5% and the trade deficit narrowed 23% month-on-month (MoM). However, the State Bank's reserves dipped slightly by $7 million, settling at $11.5 billion. On a day-on-day basis, the PSX attempted once again on Monday to decisively breach the key psychological barrier of 120,000 at close but fell short, ending the session at 118,878, reflecting a decline of 813 points. It came due to profit-taking pressure at record levels. On Tuesday, the market soared to an all-time high above 120,000 points as investor optimism grew following the approval of a $800 million loan by the ADB for Pakistan's public finance programme and the government's approval of a Rs880 billion Public Sector Development Programme (PSDP). The benchmark KSE-100 index recorded an increase of 1,573 points and settled at 120,451. The bourse continued its record-breaking run on Wednesday, with the index closing at an all-time high of 121,799, up 1,348 points. Investor sentiment remained upbeat ahead of the federal budget, buoyed by expectations of fiscal relief measures and encouraging macroeconomic indicators. However, the PSX witnessed a volatile session on Thursday, with the benchmark index retreating after hitting record highs a day earlier. Investor sentiment turned cautious due to concerns about stringent conditions linked to a new IMF programme, including the proposed enforcement of agriculture income tax and the IMF's opposition to provincial energy subsidies. The PSX ended the day on a negative note at 121,641, down 158 points. "Building on last week's bullish trend, the market picked up pace, with the KSE-100 reaching an all-time high of 121,798 points on June 4, driven by buying interest across different sectors," Arif Habib Limited (AHL) wrote in its weekly report. Positive sentiment followed Pakistan's successful budget talks with the IMF, alongside the ADB's approval of a $800 million financing package. The government also finalised a Rs1.275 trillion circular debt resolution deal with banks, a significant move for the power sector, AHL said. Meanwhile, during May 2025, petroleum sales rose 10% YoY, inflation came in at 3.5% and the trade deficit narrowed 23% MoM. The State Bank's reserves declined $7 million to $11.5 billion. The market closed at 121,641, depicting a surge of 1,950 points, or 1.63% week-on-week (WoW). Sector-wise, the positive contribution came from commercial banks (1,044 points), power generation and distribution (369 points), fertiliser (206 points), food and personal care products (95 points) and chemicals (60 points). Meanwhile, the sectors that contributed negatively were technology and communication (82 points), automobile assemblers (29 points), miscellaneous (24 points), cable and electrical goods (10 points) and Real Estate Investment Trusts (five points). Scrip-wise, the positive contributors were Pakgen Power (327 points), Bank AL Habib (208 points), NBP (165 points), HBL (160 points) and Fauji Fertiliser Company (158 points). Foreigners' selling was witnessed during the week, which came in at $14.7 million compared to net selling of $5.56 million last week. Average volumes arrived at 660 million shares (-0.2% WoW) while average traded value settled at $98.6 million (up 24.9%), AHL added. Syed Danyal Hussain of JS Global wrote that the KSE-100 index hit an all-time high during the outgoing week, closing at a record level of 121,641 points, up 1.6% WoW. The rally was largely driven by optimism surrounding a potential agreement with the IMF, as indicated by the prime minister, which spurred pre-budget sentiment, he said. The government, following the IMF's endorsement, finalised a Rs1.275 trillion financing agreement with 18 commercial banks to address the power sector's circular debt. On the sectoral front, local cement dispatches rose 9% YoY in May 2025, bringing 11MFY25 volumes to nearly flat levels. Meanwhile, a 26% rise in exports during 11MFY25 lifted total cement sales to a growth of 2%, he added.
Business Recorder
18 hours ago
- Business Recorder
Pakistan's vaccine independence: a national imperative
Pakistan stands at a critical crossroads in public health policy. With seven million births annually and a population growth rate of 2.55%, our nation faces an unprecedented challenge in vaccine security that demands immediate and decisive action. The looming withdrawal of GAVI support by 2031 presents not just a crisis, but an opportunity to transform Pakistan into a self-reliant pharmaceutical powerhouse. The stark reality we face The numbers paint a sobering picture of our current vulnerability. Pakistan's complete dependency on donated and discounted vaccine supplies, supported by GAVI, UNICEF, and WHO to the tune of PKR 26 billion annually, masks a deeper structural weakness. When GAVI's support ends in 2031, the financial burden will balloon to PKR 100 billion annually as nearly four times our current federal health budget of PKR 27 billion. This dependency is not merely financial; it represents a fundamental threat to national health security. This isn't just underdevelopment—it's a systematic surrender of national health autonomy. Today, Pakistan produces virtually no antigens for the Expanded Programme on Immunization (EPI) vaccines domestically. We lack essential seed banks, have minimal university-based vaccine development programs, and operate with regulatory guidelines that are inadequate for sophisticated vaccine manufacturing. Our clinical trial expertise remains severely limited, creating bottlenecks in bringing locally developed vaccines to market. The contrast with global pharmaceutical leaders is stark. While universities worldwide have been the birthplace of revolutionary vaccines-from the Hepatitis B vaccine developed at UC San Francisco to the Oxford-AstraZeneca Covid-19 vaccine-Pakistan's academic institutions remain largely disconnected from commercial vaccine production. Learning from global success stories International experience offers valuable lessons. India transformed itself into the 'pharmacy of the world' through strategic government support for generic manufacturing and robust regulatory frameworks. Singapore built a biomedical hub through integrated research, manufacturing, and regulatory excellence that attracted billions in global pharmaceutical investment. South Korea's government-industry partnerships created world-class biopharmaceutical capabilities. These success stories share common elements: sustained government commitment, strategic investment in infrastructure, regulatory excellence, and comprehensive talent development programs. Most importantly, they demonstrate that with the right approach, developing nations can achieve pharmaceutical self-sufficiency and even become global exporters. The Triple Helix solution The path forward requires unprecedented coordination between government, academia, and industry -what experts call the 'Triple Helix' approach. Each sector must play a distinct yet interconnected role in building national vaccine capacity. Government leadership is essential in creating policy frameworks that incentivize domestic production while providing funding for university research. Strategic assignments to national research institutions like the National Institute of Health, Centre of Excellence in Molecular Biology (CEMB), National Institute for Biotechnology and Genetic Engineering (NIBGE), International Centre for Chemical and Biological sciences (ICCBS), Karachi University, Department of Biotechnology, Dow University of Health Sciences (DUHS), etc., can accelerate vaccine development and establish crucial seed banks. Most critically, the government must develop a comprehensive national health security strategy that positions vaccine self-sufficiency as a matter of national defense. The regulatory transformation cannot be understated. Pakistan's Drug Regulatory Authority must achieve WHO Level 3 qualification and create 'regulatory sandboxes — collaborative environments where university researchers, industry partners, and regulatory experts jointly develop guidelines for the 13 critical EPI vaccine antigens. Fast-track approval pathways and clear regulatory roadmaps will accelerate the journey from laboratory research to commercial production. Formation of sandboxes by bringing together leaders of the University, Regulatory and Industry. Universities must step up as innovation engines. Institutions with BSL-III laboratories should lead development of live attenuated vaccines, while biotechnology departments focus on recombinant vaccine technologies. Specialized vaccine research centers, industry-relevant curricula, and technology transfer offices will bridge the gap between academic discovery and commercial application. State-of-the-art pilot manufacturing facilities will provide proof-of-concept capabilities essential for scaling innovations. Industry brings manufacturing excellence and market expertise to the equation. Private sector partners can transform academic research into GMP-compliant commercial production, establish robust supply chains for raw materials, and navigate complex regulatory approvals. Their distribution networks and market access capabilities will ensure that domestically produced vaccines reach every corner of Pakistan. Leading companies in Pakistan already in the field of Biopharmaceutical manufacturing must be involved in the development process. A realistic implementation roadmap Success requires a phased approach spanning six years. The foundation phase (Years 1-2) must establish policy frameworks and coordination mechanisms while launching capacity-building programmes. Infrastructure development (Years 2-4) involves scaling laboratory manufacturing capabilities, establishing vaccine testing facilities, and launching pilot production programs. The scale-up phase (Years 4-6) transitions to commercial production of EPI vaccines, regulatory approvals, and distribution network establishment. Finally, the optimization phase (Year 6+) expands manufacturing capabilities, develops advanced biologics production, and positions Pakistan as a regional pharmaceutical hub. Financial innovation will be crucial. Blended financing models combining public funding, private investment, and support from institutions like the Islamic Development Bank can mobilise the substantial capital required for drug substance manufacturing facilities. The initial investment may be significant, but the long-term savings and export potential far outweigh the costs. The economic and strategic imperative The benefits extend far beyond health security. A robust domestic vaccine industry could create over 5,000 jobs and reduce import dependency by 50 percent. More importantly, it would establish Pakistan as a regional pharmaceutical hub with significant export potential to neighboring countries and the broader Islamic world. The Covid-19 pandemic demonstrated the critical importance of pharmaceutical self-reliance. Nations with domestic production capabilities could respond rapidly to their populations' needs, while others waited months for external supplies. This lesson cannot be ignored as we face an uncertain global health landscape. The time for action is now Pakistan's demographic dividend — with 65 percent of the population under 30 — represents an unprecedented opportunity to build a knowledge-based pharmaceutical sector. However, this window will not remain open indefinitely. The GAVI deadline of 2031 provides a clear timeline for action, but preparation must begin immediately. The success of this transformation depends on political will, sustained investment, and most importantly, recognition that vaccine self-sufficiency is not a luxury but a national security imperative. Countries that fail to develop domestic pharmaceutical capabilities will remain perpetually vulnerable to supply disruptions, price volatility, and foreign policy pressures. A call to national action The establishment of National and Provincial Coordination Committees bringing together leaders from academia, industry, and regulatory agencies represents the essential first step. This must be followed by a comprehensive assessment of current capabilities, development of a detailed national vaccine strategy, and launch of pilot programmes for immediate impact. Pakistan has the intellectual capital, institutional foundation and market potential to achieve vaccine independence. What we need now is the collective will to transform this potential into reality. The health and prosperity of future generations depend on the decisions we make today. The choice is clear: remain dependent on the goodwill of international donors or invest in building a self-reliant pharmaceutical sector that serves not only Pakistan's needs but positions the nation as a leader in global health innovation. The Triple Helix approach offers a proven pathway to pharmaceutical independence-we must have the courage to take it. Copyright Business Recorder, 2025
Business Recorder
a day ago
- Business Recorder
Surprise jobs gain helps Canadian dollar hold on to weekly move higher
TORONTO: The Canadian dollar edged lower against its U.S. counterpart on Friday but was holding on to a weekly gain, as stronger-than-expected domestic jobs data bolstered expectations the Bank of Canada would keep rates on hold next month. The loonie was trading nearly 0.1% lower at 1.3685 per U.S. dollar, or 73.07 U.S. cents, after moving in a range of 1.3661 to 1.3704. On Thursday, the currency touched an eight-month high at 1.3632, while it was on track for a weekly gain of 0.4%. Canada's economy added 8,800 jobs last month, compared to an expected decline of 12,500. The unemployment rate, however, climbed to 7%, its highest level in almost nine years, excluding the peak of the COVID-19 pandemic. 'A lot of part-time jobs were lost and they became full-time jobs. Net-net I think it's a good thing,' said Marc Chandler,chief market strategist at Bannockburn Global Forex LLC. 'It's also clear that the Bank of Canada is not going to be in a hurry to cut rates again. There still might be another rate cut coming but later this year.' Investors see a 73% chance the BoC keeps its benchmark interest rate on hold at 2.75% in July, up from 67% before the data. On Wednesday, the central bank refrained from cutting rates for a second straight meeting, citing the need to study the effects of U.S. trade policy. U.S. jobs data was also stronger than expected, which boosted the U.S. dollar against a basket of major currencies. The price of oil, one of Canada's major exports, rose on optimism about U.S.-China trade talks. U.S. crude oil futures traded nearly 2% higher at $64.62 a barrel. Canadian bond yields moved higher across the curve, tracking moves in U.S. Treasuries. The 10-year was up 7.2 basis points at 3.327%, trading at its highest level since May 26.
